CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

被引：0
作者：
Liu, Jie [2 ]
Xu, Mengyuan [1 ]
Zhang, Xiaoqian [1 ]
Zhang, Zhuo [1 ]
Zhong, Tao [1 ]
Yu, Hongjuan [2 ]
Fu, Yueyue [2 ]
Meng, Hongbin [2 ]
Feng, Jiawei [1 ]
Zou, Xindi [1 ]
Han, Xueying [1 ]
Kang, Liqing [3 ]
Yu, Lei [3 ]
Li, Limin [1 ,2 ]
机构：
[1] South Univ Sci & Technol Hosp, Dept Hematol, Shenzhen 518000, Guangdong, Peoples R China
[2] Harbin Med Univ, Inst Hematol & Oncol Heilongjiang Prov, Dept Hematol, Affiliated Hosp 1, Harbin, Peoples R China
[3] Shanghai Unicar Therapy Biomed Technol Co Ltd, Shanghai, Peoples R China
来源：
HELIYON | 2024年 / 10卷 / 13期
关键词：
B -cell acute lymphoblastic leukemia; Allogeneic hematopoietic stem cell; transplantation; Chimeric antigen receptor -T; Refractory; Relapsed; VERSUS-HOST-DISEASE; MINIMAL RESIDUAL DISEASE; MANAGEMENT; DIAGNOSIS; EFFICACY; SAFETY;
D O I：
10.1016/j.heliyon.2024.e33937
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies. Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %. Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone. In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
引用
收藏
页数：10
相关论文
共 33 条
  • [1] G-CSF treatment of healthy pediatric donors affects their hematopoietic microenvironment through changes in bone marrow plasma cytokines and stromal cells
    Aerts-Kaya, Fatima
    Kilic, Emine
    Kose, Sevil
    Aydin, Gozde
    Cagnan, Ilgin
    Kuskonmaz, Baris
    Uckan-Cetinkaya, Duygu
    [J]. CYTOKINE, 2021, 139
  • [2] Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL
    Bader, P
    Hancock, J
    Kreyenberg, H
    Goulden, NJ
    Niethammer, D
    Oakhill, A
    Steward, CG
    Handgretinger, R
    Beck, JF
    Klingebiel, T
    [J]. LEUKEMIA, 2002, 16 (09) : 1668 - 1672
  • [3] Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi, Adriana
    Di Maio, Lucia
    Silvestri, Daniela
    Songia, Simona
    Bonanomi, Sonia
    Rovelli, Attilio
    Conter, Valentino
    Biondi, Andrea
    Cazzaniga, Giovanni
    Valsecchi, Maria G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (03) : 396 - 408
  • [4] Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines
    Brown, Patrick A.
    Wieduwilt, Matthew
    Logan, Aaron
    DeAngelo, Daniel J.
    Wang, Eunice S.
    Fathi, Amir
    Cassaday, Ryan D.
    Litzow, Mark
    Advani, Anjali
    Aoun, Patricia
    Bhatnagar, Bhavana
    Boyer, Michael W.
    Bryan, Teresa
    Burke, Patrick W.
    Coccia, Peter F.
    Coutre, Steven E.
    Jain, Nitin
    Kirby, Suzanne
    Liu, Arthur
    Massaro, Stephanie
    Mattison, Ryan J.
    Oluwole, Olalekan
    Papadantonakis, Nikolaos
    Park, Jae
    Rubnitz, Jeffrey E.
    Uy, Geoffrey L.
    Gregory, Kristina M.
    Ogba, Ndiya
    Shah, Bijal
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05): : 414 - 423
  • [5] Deconstructing the Kaplan-Meier curve: Quantification of treatment effect using the treatment effect process
    Devlin, Sean M.
    O'Quigley, John
    [J]. CONTEMPORARY CLINICAL TRIALS, 2023, 125
  • [6] ACUTE GRAFT-VERSUS-HOST DISEASE - GRADE AND OUTCOME IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
    GRATWOHL, A
    HERMANS, J
    APPERLEY, J
    ARCESE, W
    BACIGALUPO, A
    BANDINI, G
    DIBARTOLOMEO, P
    BOOGAERTS, M
    BOSI, A
    CARRERAS, E
    DEVERGIE, A
    FERRANT, A
    FIBBE, WE
    FRASSONI, F
    GAHRTON, G
    GOLDMAN, J
    IRIONDO, A
    JACOBSEN, N
    KOLB, HJ
    LINK, H
    MICHALLET, M
    PRENTICE, HG
    REIFFERS, J
    VONRHEE, F
    RUUTU, T
    SCHWAIGHOFER, H
    VERNANT, JP
    DEWITTE, T
    NIEDERWIESER, D
    [J]. BLOOD, 1995, 86 (02) : 813 - 818
  • [7] Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy
    Hay, Kevin A.
    Gauthier, Jordan
    Hirayama, Alexandre V.
    Voutsinas, Jenna M.
    Wu, Qian
    Li, Daniel
    Gooley, Ted A.
    Cherian, Sindhu
    Chen, Xueyan
    Pender, Barbara S.
    Hawkins, Reed M.
    Vakil, Aesha
    Steinmetz, Rachel N.
    Schoch, Gary
    Chapuis, Aude G.
    Till, Brian G.
    Kiem, Hans-Peter
    Ramos, Jorge D.
    Shadman, Mazyar
    Cassaday, Ryan D.
    Acharya, Utkarsh H.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    [J]. BLOOD, 2019, 133 (15) : 1652 - 1663
  • [8] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
    Hayden, P. J.
    Roddie, C.
    Bader, P.
    Basak, G. W.
    Bonig, H.
    Bonini, C.
    Chabannon, C.
    Ciceri, F.
    Corbacioglu, S.
    Ellard, R.
    Sanchez-Guijo, F.
    Jaeger, U.
    Hildebrandt, M.
    Hudecek, M.
    Kersten, M. J.
    Koehl, U.
    Kuball, J.
    Mielke, S.
    Mohty, M.
    Murray, J.
    Nagler, A.
    Rees, J.
    Rioufol, C.
    Saccardi, R.
    Snowden, J. A.
    Styczynski, J.
    Subklewe, M.
    Thieblemont, C.
    Topp, M.
    Ispizua, A. U.
    Chen, D.
    Vrhovac, R.
    Gribben, J. G.
    Kroeger, N.
    Einsele, H.
    Yakoub-Agha, I
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (03) : 259 - 275
  • [9] Anti-CD19 CAR-T cell therapy bridge to HSCT decreases the relapse rate and improves the long-term survival of R/R B-ALL patients: a systematic review and meta-analysis
    Hu, Linhui
    Charwudzi, Alice
    Li, Qian
    Zhu, Weiwei
    Tao, Qianshan
    Xiong, Shudao
    Zhai, Zhimin
    [J]. ANNALS OF HEMATOLOGY, 2021, 100 (04) : 1003 - 1012
  • [10] CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
    Hu, Yongxian
    Zhou, Yali
    Zhang, Mingming
    Ge, Wengang
    Li, Yi
    Yang, Li
    Wei, Guoqing
    Han, Lu
    Wang, Hao
    Yu, Shuhui
    Chen, Yi
    Wang, Yanbin
    He, Xiaohong
    Zhang, Xingwang
    Gao, Ming
    Yang, Jingjing
    Li, Xiuju
    Ren, Jiangtao
    Huang, He
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (10) : 2764 - 2772
1234